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Structured Abstract 
Objective: To study the three cycles effect on primary dysmenorrhea of the monophasic 24/4 
estradiol/nomegestrol acetate (E2/NOMAC) oral contraceptive and of a 21/7 ethinyl-
estradiol/chlormadinone acetate (EE/CMA) association. The tolerability and the effect on 
metabolism and health-related quality of life of both preparations were also evaluated. 
Design: Prospective observational cohort study. 
Setting: Tertiary gynecologic center for pelvic pain. 
Patients: Subjects with primary dysmenorrhea requiring an oral contraceptive, who spontaneously 
selected either E2/NOMAC (n=20) or EE/CMA (n=20). 
Main Outcome Measures: Visual Analogue Scale (VAS) score for dysmenorrhea, Short Form-36 
questionnaire for health-related quality of life, lipoproteins and days of menstrual bleeding 
(withdrawal bleeding during oral contraceptive). 
Results: Mean age and BMI were similar between the two groups. The final analysis was 
performed on 34 women, 15 in E2/NOMAC and 19 in EE/CMA group. Compliance with treatment 
was significantly higher with EE/CMA (100%) than E2/NOMAC (75%) (p=0.038). Both treatments 
significantly (p<0.0001) reduced VAS of primary dysmenorrhea, similarly (E2/NOMAC by a mean 
of 74.7%, EE/CMA by a mean of 78.4%; p=0.973). Only E2/NOMAC significantly increased SF-
36 score (p=0.001), both in physical (p=0.001) and mental domains (p=0.004). The mean number of 
days of menstrual bleeding was significantly reduced in E2/NOMAC group (from 4.86±1.20 days 
to 2.64±1.59 days, p=0.0005 vs. baseline, p=0.007 vs. EE/CMA group). BMI did not vary in either 
group. E2/NOMAC did not change lipoproteins and Apoproteins while EE/CMA increased total 
cholesterol (p=0.0114), HDL-cholesterol (p=0.0008), tryglicerides (p=0.002), Apo-A1 (p=0.0006) 
and Apo-B (p=0.008) and a decrease of LDL/HDL ratio (p=0.024). 
Conclusions  
Both oral contraceptives reduced similarly dysmenorrhea, with E2/NOMAC also reducing 
withdrawal bleedings, and being neutral on lipid metabolism. 
 Keywords: primary dysmenorrhea, estradiol, ethinylestradiol, nomegestrol acetate, chlormadinone 
acetate, metabolism, side effects, quality of life, tolerability.   
Main text 
Introduction 
Background/Rationale 
Dysmenorrhea is a very common disease with a prevalence up to 90% of women in reproductive 
age[1]. It can be classified in, As the consequence of an absent or present  underlying organic cause 
dysmenorrhea can be classified as primary or secondary, respectively. For women who wish 
contraception, combined oral contraceptives (COCs) are the preferential therapy for pain relief 
[2,3]. Among all COCs, the monophasic  21/7 regimen COC containing chlormadinone acetate 
(CMA) in a dosage of 2 mg combined with 30 mcg of ethinyl-estradiol (EE) seems to be one of the 
most effective preparation [2]. The effect of this particular preparation was widely demonstrated in 
large clinical trials, even when other hormonoal contraceptives failed  [5,6]. The relevant 
therapeutic effect has to be ascribed to CMA, which is capable to reduce prostaglandin synthesis by 
down-regulating the key enzyme cyclo-oxygensae 2 (COX-2)[4]. CMA also exerts partial 
glococorticoid activity whose role in reducing dysmenorrhea [2], remains to be elucidated [4].  
A new COC was recently introduced in the market, an association between 17β estradiol (E2) and 
nomegestrol acetate (NOMAC) in a monophasic 24/4 regimen [7]. Recently, a pooled analyses of 
two large randomized, open-label studies reported that this preparation is associated with a 
significant reduction of menstrual pain and cramps when compared with a COC containing EE and 
drospirenone [8]. No other comparative data on dysmenorrhea is available between E2/NOMAc 
association and other COCs . 
Main objective of this observational study is to verify the effect on primary dysmenorrhea of the 
monophasic 24/4 E2/NOMAC COC in comparison to that exerted by one of the most effective 
COC for the treatment of dysmenorrhea such as the monophasic 21/7 EE/CMA association. 
Secondary objectives of the study were to observe the effect on quality of life, tolerability, and 
metabolism of these two formulations. 
Materials and methods 
This was a prospective observational mono-centric study, performed at a University Hospital 
service for chronic pelvic pain between January 2012 and June 2014. It was conducted in full 
accordance with the World Medical Association Declaration of Helsinki and it was approved by the 
Internal Review Board of our department,  
Women suffering from menstrual pain from more than 12 months, of normal weight (BMI < 25), 18 
to 35 years old, with no contraindication to the use of COC (WHO, 2009) [9], with regular 
menstrual cycles (cycle length between 26 and 30 days) and requiring an hormonal contraceptive 
were eligible for the study. Exclusion criteria were presumptive causes for secondary 
dysmenorrhea, demonstrated by a routine transvaginal scan of the pelvis 
(endometriosis/adenomyosis, fibroids, pelvic congestion syndrome, pelvic adhesions, etc.) or 
previous pelvic surgery (laparoscopy or laparotomy).  
Counseling presenting the different hormonal contraceptives was performed to each woman, and 
those that spontaneously chose one of the two COCs under investigation, were enrolled into the 
study. Once enrolled each woman signed an informed consent for the use of her sensitive data. The 
COCs under investigation were a monophasic oral contraceptive containing 24 tablets of 1.5 mg E2 
and 2.5 mg NOMAC + 4 placebo pills (Zoely®, Teva Italia, Milan, Italy) and a monophasic oral 
contraceptive containing 21 tablets of 30 µg EE and 2 mg CMA + 7 days of drug-free interval 
((Lybella®, Alfa Wassermann Formenti, Milan, Italy). Each patient paid her own medicine as in 
real life condition.  
The investigation consisted in two evaluations. Prior to treatment, during the early follicular phase 
of the menstrual cycle (3–5 days after spontaneous menstruation), anthropometric measures, a blood 
sample were collected. Intensity of dysmenorrhea as the “worst pain experienced during withdrawal 
bleeding days”, was evaluated by a 10 cm visual analogue scale (VAS), [10] and health related 
quality of life was evaluated by the Italian translation of the SF-36 questionnaire [11]. Height was 
measured barefoot and weight with the subject wearing light clothes without shoes. BMI (Kg/m2) 
was calculated. All the measurements were repeated during the fourth cycle of COC administration, 
3–5 days after withdrawal bleeding. During the 3 months women were requested to daily fill a diary 
reporting days of spotting and bleedings. 
 
Blood samples 
All blood samples were collected in the morning, after 12 h of fasting, into tubes placed on ice and 
immediately centrifuged. An aliquot of serum was immediately tested for glucose, and another 
aliquot was used for the determination of total cholesterol, HDL-cholesterol, total triglycerides, 
apoprotein-A1 (Apo-A1) and apopoprotein-B (Apo-B). 
Glucose was determined by enzymatic method (instrument Cobas c 501, Q3 Roche, Mannheim, 
Germany). Plasma total cholesterol and triglycerides were obtained by enzymatic colorimetric 
methods (instrument Cobas c 501, Roche), while HDL-cholesterol was measured by enzymatic 
colorimetric homogeneous methods (Instrument Cobas c 501, Roche). LDL-cholesterol levels were 
calculated by the Friedewald formula. Apo-A1 and Apo-B were measured by an 
immunonephelometric method Q3 (Instrument BN II, Siemens, München, Germany). All analyses 
were performed in the same laboratory. 
 
Data analysis 
Statistical analysis was performed using the statistical package StatView (version 5.01.98, SAS 
Institute Inc, Cary, NC, USA). Data were analyzed by one of the authors (G. G.) who was blinded 
to the specific treatment of each woman. Intragroup comparison was performed by the t test for 
paired data or by the Wilcoxon signed-rank test for normal and non-normal distribution of data, 
respectively. For all analyses, the null hypothesis was rejected at a two-tailed p value <0.05. Results 
are expressed as the mean±standard deviation (SD).  
 
Sample size determination 
Sample dimension of the study group was calculated on possible menstrual pain VAS modification. 
A previous study showed COC-induced reduction of VAS score for menstrual pain of 4 points with 
a SD of 2 [12]. By setting type I error at 0.05 and type II error at 0.20, 4 subjects would have been 
necessary to document a significant variation within group. Similarly in order to evaluate non-
inferiority of one treatment over the other we assumed that the reduction of VAS induced by either 
treatment was within 1 SD of the difference (i.e a value of 2). With these values a total sample size 
of 30 women was necessary to document a non-inferiority of one treatment vs. the other. 
Enrollment was closed when 40 women were enrolled, 20 for each group. 
 
 
 
 
 
 
 
 
 
 
 
Results 
A total of 40 women were included in the study, equally divided 20 in E2/NOMAC and 20 in 
EE/CMA group. Mean age and BMI were similar between groups (Table 1). In the E2/NOMAC 
group 5 out of 20 (25%) women interrupted the treatment: 2 (10%) during the first cycle for 
continuous headache, 2 (10%) during the second cycle for bloating and increased appetite and 1 
(5%) during the third cycle for occasional headache and bloating. One woman who initially 
requested EE/CMA did not start the treatment for lack of need of contraception. The final analysis 
was then performed on 34 women, 15 in the E2/NOMAC and 19 in EE/CMA group. During the 
first three cycles of treatment compliance with treatment was significantly greater with EE/CMA 
(100%) than E2/NOMAC (75%) (p=0.038). Two women in E2/NOMAC group and one in 
EE/CMA experienced spotting during the first two cycles of treatment, that resolved in the third 
cycle.   
 
Mean objectives 
Both treatments significantly (p<0.0001) and similarly (p=0.973) reduced VAS of menstrual pain 
(E2/NOMAC by a mean of 74.7%, EE/CMA by a mean of 78.4%) (Figure 1). Only E2/NOMAC 
significantly increased SF-36 score (p=0.001), both in physical (p=0.001) and mental domains 
(p=0.004) (Table 1). The mean number of days of menstrual bleeding (withdrawal bleeding during 
COC treatment) did not change during EE/CMA but was significantly reduced by E2/NOMAC 
(from 4.86±1.20 days to 2.64±1.59 days, p=0.0005 vs. baseline, and p=0.007 vs. EE/CMA group) 
(Table1).  
 
Secondary objectives 
With both treatments BMI did not change from baseline values (Table 1). The three cycles of 
treatment with E2/NOMAC did not change lipoprotein, tryglicerides, apoproteins and fasting 
glucose (Table 2). Conversely the three cycles of treatment with EE/CMA induced an increase of 
total cholesterol (p=0.0114), HDL-cholesterol (p=0.0008), tryglicerides (p=0.002), Apo-A1 
(p=0.0006) and Apo-B (p=0.008) and a decrease of LDL/HDL ratio (p=0.024), Lipid modifications  
were significant also vs. those induced by E2/NOMAC (Table 2). 
Discussion 
Key results 
This observational study demonstrates that a monophasic oral contraceptive composed by 24 days 
of E2 and NOMAC is as effective as the monophasic 21 days association of EE/CMA in improving 
primary dysmenorrhea. This effect is associated with a reduction of days of menstrual bleeding only 
in subjects receiving E2/NOMAC. This pain improvement is associated with an increased quality of 
life particularly in those receiving E2/NOMAC. The effect of E2/NOMAC is neutral on weight and 
lipid metabolism, while EE/CMA increases total cholesterol, HDL-cholesterol, tryglicerides and 
apoproteins and decreases LDL/HDL ratio. The three-cycles compliance to treatment was major in 
subjects in treatment with EE/CMA. 
 
Interpretation 
COCs, providing in general some relief from dysmenorrhea, are recommended as a first-line 
treatment option for women with primary dysmenorrhea who wish contraception. However, not all 
COC formulations are equally effective on this complaint. 
EE/CMA seems one of the formulations providing a more pronounced relief of dysmenorrhea when 
compared with other hormonal contraceptive formulations [2,4-6]. Its efficacy is probably due to a 
direct effect of CMA on prostaglandin synthesis, by a down-regulation of cyclo-oxygensae 2 (COX-
2) [2, 4] and a specific glucocorticoidal partial activity [2]. In one study [13], it was documented a 
EE/CMA is associated with a complete resolution of menstrual pain in 61.1% of switcher from 
other hormonal contraceptive formulations, especially in those women with frequent dysmenorrhea. 
In a prospective observational study carried out in 170 healthy females, a progressive and 
significant reduction of mild and moderate dysmenorrhea was found in the EE/CMA group in 
comparison to EE/DRSP group [14]. 
Extended regimen of COCs with a shorter hormone free interval (i.e.. 24/4- and 26/2-day regimens) 
were shown to be beneficial for menstrual cycle complaints, including menstrual pain [15]. In 
general, a simple and shared hypothesis is that fewer days of menstrual bleeding might be 
associated with less dysmenorrheic pain.  
It might be expected that E2/NOMAC with its shortened hormone free interval to 4 days would 
have a favorable effect on primary dysmenorrhea compared with an established COC used in a 
21/7-day regimen. A potent anti-gonadotropin progestogen like NOMAC that can stabilize the 
endometrium combined with E2, is associated with a tolerable and acceptable bleeding profile and 
few symptoms attributable to the hormone-free interval, such as dysmenorrhea. Indeed, in the 
present study we showed that the length of menstrual bleeding is significantly shortened by 
E2/NOMAC.  
Quality of life is associated with the intensity of pelvic pain: in particular it is inversely related to 
inter-menstrual pelvic pain but also, less stringently, to dysmenorrhea [10]. Accordingly the 
reduction of dysmenorrhea was associated with an improvement of helath related qualiy of life that 
reached the significance in the E2/NOMAC group. 
The effect of EE/CMA on lipoproteins was similar to what previously reported for this formulation, 
with an increase of HDL-cholesterol and tryglicerides and a decrease of LDL/HDL-cholesterol 
[16,17]. 
E2/NOMAC was more neutral on lipid metabolism, with no modification of lipoproteins and 
apoproteins. These effects were in accordance with those reported in a previous larger randomized 
study where this formulation was compared to the EE/levonorgestrel association [18]. NOMAC 
does not give modification of lipoproteins also when given alone in a dose of 5 mg/day [19]. Lack 
of modification observed during E2/NOMAC may thus indicate the non-capability of the weak 
estrogen E2 to modify lipoprotein profile, as recently proposed for the other estradiol-based COC 
containing estradiol valerate and dienogest in a quadriphasic association [16].  
Limitations 
One limitation of the study is the small sample of subjects included. Accordingly this can be 
considered a pilot study with preliminary results. The observational design is another important 
concern of the study, with no randomization of subjects to the different treatment groups. However, 
no difference was found between the baseline characteristics of the women enrolled in the two 
groups and data report a situation of real life condition. The study was conducted in a single center 
in Caucasian women and the results cannot be generalized. For all these reason the results should be 
considered preliminary, but worthy to be explored in larger comparative investigations. 
 
Conclusion 
The association of E2/NOMAC seems effective as the association of EE/CMA in reducing 
menstrual pain. This effect is associated with a greater reduction of menstrual bleeding and a 
reduced impact on lipid metabolism. 
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Tables MANCA LA VAS???? Due tabelle una per gli effetti uno per il metabolismo 
Table I Mean (+SD) parameters and scores of visual analogue scale for dysmenorrhea (VAS), and 
of the Short Form-36 questionnaire (SF-36) for health-related quality of life, observed in healthy 
women before and after 3 cycles of treatment with estradiol/nomegestrol acetate (E2/NOMAC; 
n=15) or ethinyl-estradiol and chlormadinone acetate (EE/CMA; n=19).  
 E2/NOMAC (n=15) EE/CMA (n=19)  
 Before During P Before During P p 
intergroup 
Age yrs. 31.23±6.93   31.07±7.02   0.953 
BMI  22.93±4.28 19.65±9.44 0.191 22.69±3.69 22.93±3.71 0.221 0.168 
Menstrual bleeding 
length (n days) 
4.86±1.20 2.64±1.59 0.0005 5.07±1.07 4.57±0.67 0.160 0.007 
VAS Dysmenorrhea        
SF-36 total 68.52±18.19 77.13±12.81 0.001 68.60±16.61 73.17±21.13 0.416 0.523 
SF-36 Physical 64.17±22.30 73.91±17.31 0.001 65.49±17.79 76.16±21.45 0.071 0.992 
SF-36 Mental 71.18±17.89 80.12±11.09 0.004 66.80±22.02 69.29±23.71 0.706 0.420 
 
Table 2. Mean (+SD) metabolic parameters observed in healthy women before and after 3 cycles of 
treatment with estradiol/nomegestrol acetate (E2/NOMAC; n=15) or ethinyl-estradiol and 
chlormadinone acetate (EE/CMA; n=19).  
 
 E2/NOMAC (n=15) EE/CMA (n=19)  
 Before During P Before During P p 
intergroup 
T-Chol mmol/L     4.77±0.44 4.59±0.21 0.251 4.49±0.65  5.06±1.10 0.0114 0.006 
HDL-C mmol/L 1.70±0.44 1.60±0.44 0.214 1.59±0.29 1.92±0.30 0.0008 0.0005 
LDL-C mmol/L 2.90±0.64 2.84±0.36 0.650 2.74±0.54 2.84±0.91 0.545 0.194 
LDL/HDL  1.70±0.30 1.77±0.45 0.547 1.72±0.26 1.48±0.42 0.024 0.031 
T Chol/HDL  2.55±0.72 2.87±0.73 0.112 2.82±0.34 2.63±0.89 0.224 0.124 
Triglycerides 
mmol/L 
0.87±0.28 0.75±0.20 0.420 0.78±0.32 1.48±0.62 0.002 0.006 
Apo-A1 g/dL 1.68±0.18 1.57±0.23 0.121 1.59±0.23 2.07±0.37 0.0006 0.002 
Apo-B g/dL 0.84±0.16 0.91±013. 0.436 0.65±0.12 0.80±0.24 0.008 0.321 
Apo-A1/Apo-B     2.00±0.37 1.72±0.44 0.218 2.44±0.40 2.59±0.84 0.261 0.154 
Fasting glucose 
mmol/L 
4.88±0.31 4.85±0.63 0.881 5.09±0.52 4.98±0.54 0.274 0.616 
 
 
Legend for Figures 
 
Figure 1. Intensity of primary dysmenorrhea expressed in visual analogic score in women before 
and after three cycles of treatment with E2/NOMAC or EE/CMA.  
* p < 0.0001 vs. baseline 
 
 
Figure 2. Length of menstrual bleeding expressed in number of days in women before and after 
three cycles of treatment with E2/NOMAC or EE/CMA.  
* p < 0.0001 vs. baseline; ** p < 0.01 vs. EE/CMA 
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